Merck/Sanofi Pasteur (MSP)
Vaxelis™ the much anticipated hexavalent vaccine developed collaboratively between Merck & Sanofi Pasteur is finally available! Approved by the FDA in 2018 and given the recommendation by the ACIP, Vaxelis™ will be an important leap forward in reducing the number of injections required for infant immunization.
The Vaxelis™ pricing program is a separate and new contract from other Sanofi Pasteur vaccines. For member practices who are interested in qualifying for the performance pricing, there is a marketshare component. For details please reach out to us at (818) 332-7057 or by e-mail at ten.gppmnull@ofni.
MPPG Members may participate in the Vaxelis™ performance pricing program by completing the performance pricing form.
More details about Vaxelis™ may be found at website www.vaxelis.com